3/5
06:06 pm
evmn
Evommune, Inc. GAAP EPS of -$11.22, revenue of $13M [Seeking Alpha]
Medium
Report
Evommune, Inc. GAAP EPS of -$11.22, revenue of $13M [Seeking Alpha]
3/5
04:35 pm
evmn
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights [Yahoo! Finance]
Medium
Report
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights [Yahoo! Finance]
3/5
04:01 pm
evmn
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
Medium
Report
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
2/18
02:14 pm
evmn
Evommune (NYSE:EVMN) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Low
Report
Evommune (NYSE:EVMN) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
2/12
08:30 pm
evmn
Evommune Announces $125 Million Private Placement
High
Report
Evommune Announces $125 Million Private Placement
2/10
02:13 pm
evmn
Evommune (NYSE:EVMN) had its "outperform" rating reaffirmed by analysts at Evercore ISI.
Low
Report
Evommune (NYSE:EVMN) had its "outperform" rating reaffirmed by analysts at Evercore ISI.
2/10
01:32 pm
evmn
Evommune (NYSE:EVMN) had its price target raised by analysts at HC Wainwright from $35.00 to $65.00. They now have a "buy" rating on the stock.
Low
Report
Evommune (NYSE:EVMN) had its price target raised by analysts at HC Wainwright from $35.00 to $65.00. They now have a "buy" rating on the stock.
2/10
07:30 am
evmn
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis
High
Report
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis
2/4
06:41 pm
evmn
Evommune (NYSE:EVMN) is now covered by analysts at
Weiss Ratings. They set a "sell (e)" rating on the stock.
High
Report
Evommune (NYSE:EVMN) is now covered by analysts at
Weiss Ratings. They set a "sell (e)" rating on the stock.
1/22
09:00 am
evmn
Evommune (NYSE:EVMN) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $42.00 price target on the stock.
Medium
Report
Evommune (NYSE:EVMN) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $42.00 price target on the stock.
1/7
07:00 pm
evmn
Evommune (NYSE:EVMN) was upgraded by analysts at The Goldman Sachs Group, Inc. to a "buy" rating.
Medium
Report
Evommune (NYSE:EVMN) was upgraded by analysts at The Goldman Sachs Group, Inc. to a "buy" rating.
1/7
07:00 pm
evmn
Evommune (NYSE:EVMN) was given a new $40.00 price target on by analysts at Raymond James Financial, Inc..
Medium
Report
Evommune (NYSE:EVMN) was given a new $40.00 price target on by analysts at Raymond James Financial, Inc..
1/7
06:01 pm
evmn
Evommune (NYSE:EVMN) is now covered by analysts at Raymond James Financial, Inc.. They set a "strong-buy" rating on the stock.
Medium
Report
Evommune (NYSE:EVMN) is now covered by analysts at Raymond James Financial, Inc.. They set a "strong-buy" rating on the stock.
1/7
07:11 am
evmn
Evommune (NYSE:EVMN) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.
Low
Report
Evommune (NYSE:EVMN) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.
1/6
07:17 am
evmn
Evommune (NYSE:EVMN) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.
Low
Report
Evommune (NYSE:EVMN) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.
12/14
01:27 am
evmn
Low
Report
12/11
04:58 pm
evmn
Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]
12/11
04:21 pm
evmn
Evommune, Inc. GAAP EPS of -$8.07, revenue of $10M [Seeking Alpha]
Medium
Report
Evommune, Inc. GAAP EPS of -$8.07, revenue of $10M [Seeking Alpha]
12/11
04:05 pm
evmn
Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update
Medium
Report
Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update
12/6
01:36 am
evmn
High
Report